Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Study sponsor: MacroGenics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2009-01-21Actual
Enrollment · participants2Actual
Source updated2023-11-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.